Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 454.80
-5.20 (-1.13%)
Sep 4, 2026, 5:29 PM CET
STO:SOBI Revenue
Swedish Orphan Biovitrum AB had revenue of 7.84B SEK in the quarter ending June 30, 2026, with 27.00% growth. This brings the company's revenue in the last twelve months to 30.62B, up 13.54% year-over-year. In the year 2025, Swedish Orphan Biovitrum AB had annual revenue of 28.24B with 8.50% growth.
Revenue (ttm)
30.62B
Revenue Growth
+13.54%
P/S Ratio
5.16
Revenue / Employee
14.45M
Employees
2,119
Market Cap
157.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.24B | 2.21B | 8.50% |
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
| Dec 31, 2019 | 14.25B | 5.11B | 55.90% |
| Dec 31, 2018 | 9.14B | 2.63B | 40.37% |
| Dec 31, 2017 | 6.51B | 1.31B | 25.10% |
| Dec 31, 2016 | 5.20B | 1.98B | 61.23% |
| Dec 31, 2015 | 3.23B | 620.89M | 23.82% |
| Dec 31, 2014 | 2.61B | 430.28M | 19.77% |
| Dec 31, 2013 | 2.18B | 253.53M | 13.18% |
| Dec 31, 2012 | 1.92B | 12.33M | 0.65% |
| Dec 31, 2011 | 1.91B | 4.09M | 0.21% |
| Dec 31, 2010 | 1.91B | 609.77M | 47.01% |
| Dec 31, 2009 | 1.30B | 156.39M | 13.71% |
| Dec 31, 2008 | 1.14B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.58B |
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.93M |
| Cinclus Pharma Holding AB | 35.18M |
| Nanexa AB | 33.86M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 16.60M |
| Dicot Pharma AB | 200.00K |
Swedish Orphan Biovitrum AB News
- 17 days ago - Swedish Orphan Biovitrum AB Slides: SEB Nordic Large Cap Seminar presentation - Filings
- 25 days ago - Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO - Nasdaq
- 25 days ago - Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma - Nasdaq
- 7 weeks ago - Swedish Orphan Biovitrum AB Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - Swedish Orphan Biovitrum AB Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Swedish Orphan Biovitrum AB Slides: Q2 2026 - Filings
- 4 months ago - Swedish Orphan Biovitrum AB Earnings Call Transcript: Q1 2026 - Transcripts
- 4 months ago - Swedish Orphan Biovitrum AB Quarterly report: Q1 2026 - Filings